Louise Proulx

Louise Proulx is the founder of Therillia Development Co., Inc. Current positions include Chairman at Univalor, Inc. since 2012; Director at 9342-8530 Québec, Inc., BioQuebec, Quebec Blue Cross since 2017, Canada Foundation for Innovation since 2009, Consortium Québécois sur la Découverte du Médicament, Immune Biosolutions, Inc. since 2020, Diazon Pharmaceuticals, Inc., and Tekna Plasma Systems, Inc. Also holds the role of Director-Human Resources at Tekna Plasma Systems, Inc. and Vice President-Research & Development at Canada Armed Forces.
Former roles include Chairman at Gestion Univalor LP from 2015 to 2020; Director at Gemin X Pharmaceuticals US, Inc., Centre universitaire de santé McGill, Génome Québec, Inc., National Research Council of Canada, Verlyx Pharma, Inc., and Independent Director at Celyad Oncology SA. Served as Vice President-Therapeutic Product Development at Biochem Pharma, Inc. from 1985 to 2001; Vice Principal-Research at McGill University from 2002 to 2004; Vice President-Product Development at Topigen Pharmaceuticals, Inc. in 2006 and at ViroChem Pharma, Inc. from 2006 to 2009; Vice President-Scientific Affairs at Hoechst Marion Roussel Canada, Inc. from 1985 to 2001; and Vice President at Vertex Pharmaceuticals (Canada), Inc. Education includes a doctorate from Université Laval.